Caspersen, Edouard
Guinot, Pierre-Grégoire
Rozec, Bertrand
Oilleau, Jean-Ferréol
Fellahi, Jean-Luc
Gaudard, Philippe
Lorne, Emmanuel
Mahjoub, Yazine
Besnier, Emmanuel
Moussa, Mouhamed Djahoum
Mongardon, Nicolas
Hanouz, Jean-Luc
Briant, Anaïs R.
Paul, Laure Peyro Saint
Tomadesso, Clémence
Parienti, Jean-Jacques
Descamps, Richard
Denisenko, Alina
Fischer, Marc-Olivier
,
Funding for this research was provided by:
Direction Générale de l’offre de Soins (PHRCI-19-013)
AOP Orphan
Article History
Received: 3 October 2022
Accepted: 5 May 2023
First Online: 25 May 2023
Declarations
:
: The institutional review board (IRB) of the University Hospital of Caen (Comité de Protection des Personnes Nord-Ouest III, Avenue la Côte de Nacre, Niveau 03, Porte 03–508, 14 033 Caen Cedex 9, France) approved the study for all co-investigators centers (Registration number ID RDB: 2019-A00763-54). The FAAC trial is conducted in accordance with the Declaration of Helsinki and the French laws and was registered on January 10, 2020, on the ClinicalTrials.gov website with trial identification number NCT04223739. Written informed consent will be obtained from all individual participants included in the study.
: Participants of the study signed an informed consent form. This form includes consent for publication.
: The funders had no involvement in the collection analysis and interpretation of data. The authors and investigators declare that they have no competing interests, except for JL Fellahi, JF Oilleau, E Besnier, P Gaudard, B Rozec, and N Mongardon receiving payment from AOP Orphan Pharmaceuticals.